Tel: +44 (0)1223 316 855
life science research products, biological research products, biotechnology
close ...

Product types:
Deubiquitylating Enzymes (DUBs)
GLP Compliant Safety Pharmacology Services

Optimise Your Microbiomics Workflows with ZymoBIOMICS™ Microbial Community Standards

APD Testing with iPSC Human Cardiomyocytes

Cambridge Bioscience offers access to an action potential assay (APA) service on induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from B’SYS. This animal-free assay provides a more accurate indicator of cardiac risk, at a much earlier stage in drug discovery and development, than previously available approaches. The use of iPSC-CMs provides a unique opportunity to study the effects on cardiac excitability and rhythm of potential therapeutic compounds directly on human ventricular-type myocytes not typically available for routine testing.

Benefits of Using iPSC-CMs
• Higher sensitivity using lower amounts of drug
• Better correlation between pre-clinical & clinical studies
• Higher throughput screening
• Rapid turnaround time
• Cost savings in an animal-free assay

Features of the SC-hCM APD Assay
Detects AP Prolongation, a risk factor for LQTS, EADs and Torsades de Points
Stable recordings at physiological temperature with minimal diffusion delays
Cost-effective compared to conventional methodologies
Human cell line provides accurate pre-clinical results

Request A Quote
To discuss a cardiomyocyte action potential assay project, please contact our B'SYS specialist by Clicking Here.

Contact Our B'SYS Specialist, Vashu